Amplia

Be first to know our latest company updates

Watch exclusive videos accompanying major news

Science

Board

Company Overview

Team

Values

Clinical Advisers

Corporate Directory

Corporate Governance

About Us

Presentations

In the News

Video Updates

Communication

Shareholder Services

US Shareholders

Investor Fact Sheet

Share Price

Announcements

Reports

Research Reports

Investor FAQs

Updates

Top 20 Shareholders

Investor Centre

Clinical Trial

Home

Webinars

Contact

Montserrat

Amplia Therapeutics Limited

upload.jpg

Amplia Therapeutics is pleased to announce that a poster, detailing a series of preclinical studies in pancreatic cancer models, was presented overnight at the American Association for Cancer Research (AACR) Special Conference in Cancer Research: Pancreatic Cancer, currently being held in Boston, USA.

The poster shows data demonstrating that in disease-bearing mice narmafotinib (AMP945) significantly reduces pancreatic cancer associated fibrosis through inhibition of FAK activity. Further, in a number of in vivo pancreatic cancer models, narmafotinib can be utilised to improve chemotherapy response.

“We are delighted that this extensive body of research from The Garvan Institute on our best-in-class FAK inhibitor narmafotinib is being presented at such a prestigious conference. The Garvan team have done an outstanding job and this poster represents the first public disclosure of the breadth of that work demonstrating the impressive activity of the drug in these preclinical studies.”

Poster presentation at AACR Special Conference on Pancreatic Cancer